Device Trial Radar · NCT07228221
Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma
Last checked: Nov 19, 2026Latest source record: Nov 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 5, 2026
Primary completion
Aug 30, 2031
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Jonathon MyersAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Glaukos Corporation
- First posted
- Nov 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.
Conditions
- Open Angle Glaucoma
- Pigmentary Glaucoma
- Pseudoexfoliation Glaucoma
Interventions
iStent infinite trabecular micro-bypass system model iS3Device
surgery perfomed using the iStent infinite trabecular micro-bypass system model iS3
iDose TR (Travoprost intracameral Implant) 75mcgDrug
surgery performed using the iDose TR (Travoprost intracameral Implant) 75mcg
Primary outcomes
What the sponsor says the trial is designed to measure.
- IOP reduction from baselineTime frame: Diurnal IOP reduction from baseline at 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wills Eye Hosital Glaucoma Dept.
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.